Tiziana Life Sciences Stock News

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has reported further positive results from a patient with non-active secondary progressive multiple sclerosis (SPMS) being treated with the company's intranasal

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Brigham and Women's Hospital (BWH) will receive a grant to explore the use of intranasal anti-CD3 monoclonal antibody (mAb) in the nervous sy

Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced the presentation of a study entitled, 'Treatment of Alzheimer's disease by modulation of microglial neuroinflammation by nasal anti-CD3 mAb' at th

Tiziana Life Sciences Ltd said it has appointed Dr Matthew Davis as its chief medical officer and acting chief scientific officer, effective immediately. The company noted that Dr Davis will report t

Tiziana Life Sciences (NASDAQ: TLSA) reported clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program.

Tiziana Life Sciences PLC (NASDAQ:TLSA) said a second patient with Secondary Progressive Multiple Sclerosis (SPMS) in an ongoing study has shown clinical improvements following three months of treatm

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company enabling breakthrough immunotherapies via

NEW YORK, April 26, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (NASDAQ: TLSA) ("Tiziana" or the "Company"), a clinical-stage biopharmaceutical company developing alternative routes of immuno

Tiziana Life Sciences PLC (NASDAQ:TLSA) said the US Food and Drug Administration (FDA) has given permission for the enrollment of additional Secondary Progressive Multiple Sclerosis (SPMS) patients fo

NEW YORK, March 25, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company enabling breakthrough immunotherapies via novel routes of mono

NEW YORK, March 15, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company enabling breakthrough immunotherapies via novel routes

Zak's Small Cap Research has provided its feedback from a ‘key opinion leader virtual event' hosted by Tiziana Life Sciences Ltd. The set-piece was organized after the publication of encouraging dat

Monday, March 14th @ 11 am ET, registration details below Monday, March 14th @ 11 am ET, registration details below

Gainers Hycroft Mining Holding Corporation (NASDAQ: HYMC ) shares jumped 138.1% to close at $1.50 on Thursday after dropping 37% on Wednesday. AgriFORCE Growing Systems, Ltd. (NASDAQ: AGRI ) gained 102.4% to close at $3.42 after the company announced a binding letter of intent to acquire Deroose Planta NV. Enservco Corporation (NYSE: ENSV ) shares jumped 43.1% to close at $4.32 after dropping 28% on Wednesday. Hoth Therapeutics, Inc. (NASDAQ: HOTH ) gained 38.8% to close at $0.7968 following circulation of an FDA AccessData.gov listing which showed the company''s c-KIT-targeting candidate received orphan-drug designation. AquaBounty Technologies, Inc. (NASDAQ: AQB ) surged 37.8% to close at $1.93 after the company reported FY21 EPS results were higher year over year. Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX ) jumped 33.4% to close at $0.50. Almaden Minerals Ltd. (NYSE: AAU ) gained 32.9% to settle at $0.4480. Ebix, Inc. (NASDAQ: EBIX ) jumped 31.4% to settle at $41.90 on Thursday. The company recently posted upbeat quarterly sales.

Tiziana Life Sciences Ltd (NASDAQ: TLSA ) has reported clinical data in a patient with Secondary Progressive Multiple Sclerosis (SPMS) following six months of treatment with intranasally administered foralumab. In addition to being well-tolerated, both biological and clinical improvements were seen in the patient using Tiziana''s immunotherapy technology, which overcame the challenge … Full story available on Benzinga.com